Subgroups based on autoantibody status associated with clinical manifestations, <i>HLA-DRB1</i> variants, cytokines, and flare of vasculitis in childhood-onset systemic lupus erythematosus.

Front Immunol · 2026 · PMC13033651 · PMID 41918745

Europe PMC DOI

hedged sentence

0.1800

closest p · 3.6× alpha

0.1800

boldest claim

The sentences

did not reach statistical significancep = 0.180not close (p > 0.1)

Rituximab use was also more common in subgroup 2, although the difference did not reach statistical significance ( p = 0.180).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Subgroups based on autoantibody status associated with clinical manifestations, &lt;i&gt;HLA-DRB1&lt;/i&gt; variants, cytokines, and flare of vasculitis in childhood-onset systemic lupus erythematosus.

The sentences

Subgroups based on autoantibody status associated with clinical manifestations, <i>HLA-DRB1</i> variants, cytokines, and flare of vasculitis in childhood-onset systemic lupus erythematosus.